8-K: CV Sciences Secures High-Cost Debt Amidst Going Concern Warning

CV Sciences, Inc. has secured a $600,000 senior secured note, but received only $300,000 in net proceeds after significant discounts and fees, while its auditors issued a 'going concern' opinion.

Summary

• CV Sciences, Inc. (the "Company") entered into a Securities Purchase Agreement on October 6, 2025, and closed the transaction on October 7, 2025, for a Senior Secured Note with a principal amount of $600,000.
• The Company received net proceeds of $300,000 from the $600,000 note, after an original issuance discount of $150,000 and an additional $150,000 payment to the investor for modifying a prior note purchase agreement.
• An additional $13,125 was paid to the investor to cover legal and other fees.
• The Note matures on April 6, 2027, with monthly repayments of $46,153.85 commencing on April 6, 2026.
• The Note is secured by a first priority security interest in all of the Company's and its subsidiaries' assets, including intellectual property, pari passu with existing February Notes.
• In the event of certain significant defaults, the outstanding balance of the Note can increase by 20%, and by 5% for other defaults, with interest accruing at 18% per annum (or maximum legal rate) upon default.
• The Company's independent public accountants issued a 'going concern' opinion in connection with its annual report for the fiscal year ended December 31, 2023.
• Proceeds from the Initial Note are designated for new product development and working capital.
• An 'Additional Closing' for up to $750,000 in further financing is contingent upon the Company's acquisition of Extract Labs, with proceeds allocated to the acquisition's cash portion, integration costs, and working capital.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the very high cost of capital (50% effective discount on the note), the 'going concern' opinion from auditors, and the pledging of all company assets as collateral. These factors indicate significant financial distress and high risk.

Positives

• Secured $600,000 in gross financing, providing capital for operations and new product development.
• The Company can repay the Note in full earlier than due without penalty, with an 8% discount if repaid within six months of the closing date.
• Potential for additional financing of up to $750,000 upon the successful acquisition of Extract Labs.

Negatives

• The net proceeds received by the Company were only $300,000 from a $600,000 note, indicating a very high cost of capital due to a $150,000 original issuance discount and a $150,000 payment to the investor for a prior agreement modification.
• An additional $13,125 was paid to the investor for legal and other fees, further reducing net proceeds.
• The Note carries a high default interest rate of 18% per annum and mandatory default amounts of 105% or 120% of the outstanding balance upon an Event of Default.
• All of the Company's and its subsidiaries' assets, including intellectual property, are pledged as first priority collateral.
• Strict negative covenants limit the Company's ability to incur additional indebtedness, create liens, repurchase stock, pay cash dividends, or engage in certain affiliate transactions without investor consent.
• The Company's independent public accountants issued a 'going concern' opinion for the fiscal year ended December 31, 2023, raising substantial doubt about its ability to continue operations.

Risks

• Significant financial distress indicated by the 'going concern' opinion from independent public accountants.
• High cost of capital due to substantial original issuance discount and fees, which could strain future liquidity.
• Risk of accelerated repayment and increased obligations (105% to 120% of outstanding balance) upon various events of default, including non-payment, breach of covenants, cross-defaults, or bankruptcy events.
• Pledging all assets, including intellectual property, as collateral limits the Company's flexibility and ability to secure future financing.
• The Company is prohibited from incurring most new indebtedness or creating new liens, restricting future financial maneuvers.
• The potential acquisition of Extract Labs, which is a condition for additional financing, introduces integration and operational risks.
• The Purchaser holds a right of participation in future equity or debt financings, potentially limiting the Company's options for raising capital and leading to further dilution for existing shareholders.

Future Outlook

The Company plans to use the net proceeds for new product development and working capital. There is a contingent plan for additional financing tied to the potential acquisition of Extract Labs. However, the 'going concern' opinion from its auditors suggests a challenging financial future, requiring significant improvements to ensure long-term viability.

Management Comments

• Joseph Dowling, CEO of CV Sciences, Inc., signed the Securities Purchase Agreement, Senior Secured Note, Security Agreement, and Intellectual Property Security Agreement on behalf of the Company and its subsidiaries.

Industry Context

The cannabis and CBD industry often faces difficulties in accessing traditional financing due to regulatory complexities and perceived risks. This frequently leads companies in the sector to resort to more expensive, secured debt instruments with stringent covenants. The 'going concern' opinion is a severe red flag, indicating significant financial challenges that are not uncommon for companies operating in nascent or highly regulated industries, especially those undergoing rapid market shifts or facing intense competition. The potential acquisition of Extract Labs suggests a strategy of consolidation or expansion, which, while potentially beneficial, also introduces integration risks in an already challenging financial environment.

Comparison to Industry Standards

• The effective cost of capital, evidenced by the 25% original issue discount and additional fees, is significantly higher than typical corporate debt financing, aligning more with distressed or high-risk lending standards rather than healthy industry benchmarks.
• The 'going concern' opinion from the Company's independent public accountants is a critical indicator of financial instability, placing the Company well below industry standards for financial health and sustainability.
• Pledging all company assets, including intellectual property, as collateral is a common practice for lenders to companies perceived as high-risk, such as those in the cannabis sector or those facing financial difficulties, but it severely limits the Company's future financing flexibility compared to more established industry players.
• The strict negative covenants, including limitations on further indebtedness, dividends, and stock repurchases, are typical of highly leveraged or financially constrained companies, contrasting with the operational freedom enjoyed by financially robust industry peers.

Corporate Governance

Related Party Transactions

• Any transaction with an Affiliate or family member of an Affiliate exceeding $50,000 (other than disclosed agreements) requires approval by a majority of the disinterested directors of the Company.

Stakeholder Impact

• **Shareholders:** Face increased risk due to the high cost of debt, the 'going concern' opinion, and the pledging of all assets. Potential for significant dilution if future equity raises occur, and limited prospects for cash dividends or stock repurchases.
• **Creditors:** The new note holder benefits from a first priority security interest in all company assets, improving their recovery prospects in case of default. Existing February Note holders are pari passu with this new debt.
• **Management:** Operates under tighter financial constraints and covenants, requiring careful management of liquidity and strategic decisions.
• **Employees:** No direct impact mentioned, but the Company's financial distress could lead to future operational adjustments or workforce changes.

Next Steps

• The Company is required to make monthly repayments of $46,153.85 starting April 6, 2026.
• The Company may pursue the acquisition of Extract Labs, which would trigger an 'Additional Closing' for further financing.
• The Company will continue new product development and utilize funds for working capital.
• The Company needs to address the underlying issues that led to the 'going concern' opinion.

Key Dates

Recommendation

The filing reveals a company in significant financial distress, evidenced by the 'going concern' opinion from its auditors and the extremely high cost of capital for the new debt. Receiving only $300,000 in net proceeds from a $600,000 note, coupled with pledging all company assets as collateral, indicates a desperate need for liquidity and a very unfavorable risk-reward profile for equity investors. The strict covenants further limit management's flexibility. These factors collectively point to substantial downside risk for shareholders.

Keywords

CV Sciences, secured note, debt financing, capital raise, going concern, intellectual property security, Extract Labs acquisition, promissory note, corporate finance, risk management